**HIV infection of the male genital tract – consequences for sexual transmission and reproduction**

A. Le Tortorec and N. Dejucq-Rainsford

INSERM U625, Rennes; Rennes I University, Groupe d’Etude de la Reproduction chez l’Homme et les Mammifères; IFR 140, Campus de Beaulieu, Rennes, France

**Summary**

Despite semen being the main vector of human immunodeficiency virus (HIV) dissemination worldwide, the origin of the virus in this bodily fluid remains unclear. It was recently shown that several organs of the male genital tract (MGT) are infected by HIV/simian immunodeficiency virus (SIV) and likely to contribute to semen viral load during the primary and chronic stages of the infection. These findings are important in helping answer the following questions: (i) does the MGT constitute a viral reservoir responsible for the persistence of virus release into the semen of a subset of HIV-infected men under antiretroviral therapy, who otherwise show an undetectable viral load? (ii) What is the aetiology of the semen abnormalities observed in asymptomatic HIV-infected men? (iii) What is the exact nature of the interactions between the spermatozoa, their testicular progenitors and HIV, an important issue in the context of assisted reproductive techniques proposed for HIV-seropositive (HIV+) men? Answers to these questions are crucial for the design of new therapeutic strategies aimed at eradicating the virus from the genital tract of HIV+ men – thus reducing its sexual transmission – and for improving the care of serodiscordant couples wishing to have children. This review summarizes the most recent literature on HIV infection of the male genital tract, discusses the above issues in light of the latest findings and highlights future directions of research.

**Introduction**

Shortly after the first cases of acquired immunodeficiency syndrome (AIDS) were described in 1981 in the United-States, two main populations at risk were identified, homosexual men and haemophiliacs. Based on these observations, the cause of AIDS was hypothesized to be due to a sexually and blood transmitted pathogenic agent, even before the discovery of its aetiological agent, the human immunodeficiency virus (HIV). Twenty six years later, the spread of HIV has become a global phenomenon and infected more than 65 million people of whom 25 million are deceased, according to the latest estimates. In 2007, 2.7 million people were newly infected, 80% of whom were through sexual transmission.

Semen represents the main vector of HIV dissemination, evidenced by transmission occurring more efficiently from men to women and men than from women to men (Royce et al., 1997). The origin of the free viral particles and infected cells contaminating semen are still unclear. Semen is composed of cells and secretions from the testes, epididymis, prostate, seminal vesicles and bulb-urethral glands. Because of the extreme difficulty in sampling the genital organs from asymptomatic HIV+ men, the infection of the semen-producing organs has been little studied and several questions remain:

1. What is the source of virus production in the male genital tract (MGT)? It is established that the viral strains present in semen do not solely arise from the blood compartment but is/are the MGT organ(s) responsible for the seminal viral load?
2. What is the nature of the interactions among HIV, the spermatozoa and their progenitor cells the testicular germ cells?
3. Does the MGT constitute a viral reservoir resistant to current anti-HIV therapy? Highly Active Antiretroviral Therapy (HAART) does not always eradicate the virus from semen, even when achieving an undetectable viral load in blood and can favour the sexual transmission of drug-resistant strains;

4. What is the cause of the semen abnormalities recently described in HIV+ men?

Answering these questions is crucial for the design of new therapeutic strategies aimed at eradicating the virus from the genital tract of HIV+ men (thus reducing its sexual transmission) and for improving the care of sero-discordant couples wishing to have children. The aim of this review was to summarize the current knowledge on HIV infection of the male genital tract, discuss the above questions in view of the latest findings and highlight future directions of research.

Origin of HIV in semen?

HIV is present in semen as free viral particles and infected cells. It was originally believed that the only source of HIV in semen was infected lymphocytes and macrophages coming from the blood. It has now been shown that the HIV strains present in semen evolve separately from the strains in the blood or in other anatomical compartments (Kroodsma et al., 1994; Vernazza et al., 1994; Zhu et al., 1996; Byrn et al., 1997; Coombs et al., 1998; Eron et al., 1998; Hecht et al., 1998; Kiessling et al., 1998; Eyre et al., 2000; Gupta et al., 2000; Ping et al., 2000; Ghosn et al., 2004a, 2004b; Pillai et al., 2005). This indicates that the MGT constitutes a viral compartment distinct from the blood and locally produces viral particles that are under a specific selective pressure. Phylogenetic analyses showed that the free viral particles contaminating the seminal fluid are, in some cases, distinct from those isolated from the infected leucocytes present in semen (Paranipe et al., 2002; Ghosn et al., 2004b), while a subset arise because of passive diffusion from the blood (Curran & Ball, 2002; Ghosn et al., 2004b). In addition, a discrepancy between the number of infected leucocytes in semen and the viral load in the seminal plasma is often observed [reviewed in (Dejucq & Jegou, 2001; Dejucq-Rainsford & Jegou, 2004)]. Thus it appears that the seminal lymphocytes and macrophages are not the only producers of the viral particles detected in the seminal fluid and that a distinct productive source contributes to virus shedding in semen. Of interest is that HIV shedding in semen may be intermittent, a phenomenon yet to be explained and not linked to variations in the blood viral load (Coombs et al., 1998; Gupta et al., 2000; Bujan et al., 2004).

As infected leucocytes in semen produce viral strains that are different from those in blood leucocytes (Kroodsma et al., 1994; Vernazza et al., 1994; Zhu et al., 1996; Byrn et al., 1997; Coombs et al., 1998; Eron et al., 1998; Hecht et al., 1998; Kiessling et al., 1998; Eyre et al., 2000; Gupta et al., 2000; Ping et al., 2000; Ghosn et al., 2004a, 2004b; Pillai et al., 2005), this indicates that the infected leucocytes and the free virions contaminating semen have distinct origins within the male genital tract, therefore suggesting that several semen-producing organs are infected and contribute either free virus or infected cells. The potential sources of virus in the MGT are discussed below.

HIV detection within the male genital tract organs and cells

HIV & spermatozoa

The nature of HIV interaction with spermatozoa is still a matter of debate (Piomboni & Baccetti, 2000). Although the main HIV receptor CD4 is absent from spermatozoa, several alternative receptors for HIV have been described: GaAAG, a glycolipid related to galactosylceramide (an alternative receptor used by HIV in conjunction with a chemokine co-receptor to enter CD4-negative cells) (Clapham et al., 1999), is expressed by about 30% of ejaculated spermatozoa and binds the HIV envelope protein gp120 (Brogi et al., 1998; Gadella et al., 1998). However, this binding is inhibited by seminal plasma (Gadella et al., 1998), suggesting that HIV could not bind to ejaculated spermatozoa through GaAAG, although this alternative receptor could allow HIV binding to testicular or epididymal spermatozoa. The HIV co-receptor CCR5 is also expressed by spermatozoa and could, in principle, allow the fusion of HIV with spermatozoa if present in association with GaAAG (Muciaccia et al., 2005a, 2005b). The proteins and/or mRNAs of several other chemokine receptors are expressed by spermatozoa (Isobe et al., 2002; Zhang et al., 2004), some of them previously described to mediate HIV binding. Another receptor allowing the CD4-independent binding and entry of HIV in other cell types (Liu et al., 2004), the mannose receptor, was identified in about 10% of ejaculated spermatozoa and shown to bind HIV gp120 (Fanibunda et al., 2008). No internalization of gp120 was observed and it is presently unknown whether this receptor can trigger the internalization of a whole virion (Fanibunda et al., 2008). In agreement with the finding that spermatozoa express at their surface several molecules able to bind HIV particles, purified motile spermatozoa from HIV negative donors incubated with HIV in the absence of seminal plasma were shown to act as carriers and transmit the virus to susceptible leucocytes in vitro (Dussaix et al., 1993). Using electron microscopy, different groups visualized HIV particles and immuno-labelled proteins attached
or internalized into purified spermatozoa from HIV negative donors exposed to HIV in vitro (Bagasra et al., 1988; Dussaix et al., 1993; Baccetti et al., 1994; Scofield et al., 1994). One of them reported the detection of HIV particles in the ejaculated spermatozoa of HIV-positive men (Baccetti et al., 1994) and their transfer to oocytes in fertilization experiments in vitro (Baccetti et al., 1994) but these results have not been confirmed (Pudney et al., 1999).

It is generally accepted that motile spermatozoa are not productively infected by the virus. Although HIV DNA and/or RNA were detected by polymerase chain reaction (PCR) in spermatozoa purified using a gradient of Percoll without swim-up (which further separates motile spermatozoa from non-motile), these positive findings were assumed to result from contaminations of this fraction by a few remaining infected leucocytes or from false positives (Dulioust et al., 1998; Marina et al., 1998; Tachtet et al., 1999; Hanabusa et al., 2000; Leruez-Ville et al., 2002a). Indeed when PCR is performed on the highly purified motile spermatozoa fraction isolated from semen through a percoll gradient + swim-up or double tube techniques, HIV nucleic acids are generally not detected (Quayle et al., 1997; Kim et al., 1999; Hanabusa et al., 2000; Pasquier et al., 2000; Bujan et al., 2004; Politch et al., 2004; Kato et al., 2006; Persico et al., 2006; Bostan et al., 2008). Of note, however, positive results were sometimes obtained even on this highly purified spermatozoa fraction (Baccetti et al., 1994; Chrystie et al., 1998), which could result from the persistence of free viral particles despite the washes in the presence of high seminal viral load (Fiore et al., 2005). The early report of HIV DNA within both motile and non-motile spermatozoa using in situ PCR (Bagasra et al., 1994) could not be confirmed by two other teams (Pudney et al., 1999; Persico et al., 2006). In summary, most studies failed to detect HIV nucleic acids within purified motile spermatozoa, indicating that the few positive results reported represent either false positives or very rare events. Of note is that only a very small fraction of the millions of ejaculated spermatozoa are tested in PCR, inducing sampling biases which may also account for the divergent results amongst studies. Interestingly, however, a recent study using a range of techniques demonstrated the presence of HIV DNA in a subset of abnormal spermatozoa with an abnormal morphology (Muciaccia et al., 2007) – a cell population that had not been studied so far apart from the two early studies, indicating HIV interaction with non-motile spermatozoa using electron microscopy (Scofield et al., 1994) or in situ PCR (Bagasra et al., 1994). A phenomenon to bear in mind in the context of HIV detection within spermatozoa is the fact that mammalian spermatozoa spontaneously take up foreign DNA or RNA in the absence of seminal plasma (e.g. epididymal spermatozoa). Spermatozoa have the ability to reverse-transcribe RNA of viral origin into cDNA fragments, internalize them into sperm nuclei (and even in some instances integrate the foreign DNA into the sperm genome) and transfer the foreign nucleic acids to embryos upon in vitro fertilization (Spadafora, 1998; Giordano et al., 2000). Sperm interaction with foreign nucleic acids molecules triggers endogenous nucleases that cleave both exogenous and genomic DNA, eventually leading to cell death (Spadafora, 1998).

In the context of HIV infection, one hypothesis is that non-specific uptake of HIV RNA/DNA by epididymal spermatozoa would lead to abnormal spermatozoa prone to cell death, which may explain the detection of ejaculated HIV DNA+ abnormal spermatozoa by Muciaccia et al. (Muciaccia et al., 2007). Alternatively, this detection may result from specific interactions between HIV and spermatozoa.

In conclusion, spermatozoa display several receptors that could allow HIV specific binding during their progression through the male genital tract. Thus it is likely that spermatozoa can act as a carrier for viral particles encountered within the testis or epididymis, i.e. in the absence of seminal plasma, an inhibitor for some of the HIV receptors present on spermatozoa. It is established that spermatozoa do not produce HIV particles. Whether they can support the early steps of HIV replication (e.g. up to viral DNA synthesis) as proposed by some authors remains speculative, as the vast majority of studies did not evidence any HIV genetic material and spermatozoa are considered as metabolically inert cells. However, non-specific mechanisms such as foreign RNA uptake could be at play and explain the detection of HIV DNA in a subset of abnormal spermatozoa. The exact nature of the interactions between HIV and spermatozoa, and their impact on spermatozoa morphology, are far from fully understood and require further studies.

**HIV & the testis**

The infection of the testis by HIV can have important consequences for the eradication of the virus from the MGT by antiretroviral therapies. Thus, the existence of the blood testis barrier and of the drug efflux pumps of the ABC transporter family expressed by a wide range of testicular cell types, restrict the drug access to this organ, as shown for some HIV replication inhibitors (Choo et al., 2000; Livni et al., 2004). These data indicate that, if infected, the testis may represent a viral sanctuary resistant to antiviral treatments. To date, the concentration of HIV inhibitors in the human testis and in other organs of the MGT is unknown. To investigate the susceptibility of the human testis to HIV infection, our team
developed an organotypic culture of this organ (Roulet et al., 2006a) and revealed that the human testis is infected by HIV-1 ex vivo and produces low levels of infectious viral particles (Roulet et al., 2006b). The main virus-producing cells in this culture model are the resident testicular macrophages (Roulet et al., 2006b). The analysis of the in vivo infection of the testis in asymptomatic macaques infected by SIV, the simian counterpart of HIV, was recently undertaken. The experimental infection of cynomolgus macaques represents the best animal model to study HIV infection as the animals display many common features with HIV infected humans throughout the disease progression (such as the nature of the infected organs/cells and the immune responses) and they develop AIDS like humans (Haigwood, 2004). The in vivo study of SIV-infected macaques confirmed the productive infection of the testis during the asymptomatic chronic stage and revealed that this infection occurs during the acute primary infection (Le Tortorec et al., 2008a). Infected cells within the testicular interstitial tissue are macrophages and T lymphocytes, a finding in agreement with observations in chronically-infected juvenile pigtail macaques (Shehu-Xhilaga et al., 2007) and in asymptomatic HIV+ men (Mucciaccia et al., 1998; Paradjipe et al., 2002). Importantly, the presence of SIV in some isolated testicular germ cells was shown for all the animals tested, using both immunohistochemistry and in situ hybridization (Le Tortorec et al., 2008a), thus reinforcing the previous controversial observations in macaques and humans using other techniques (Mucciaccia et al., 1998; Shehu-Xhilaga et al., 2007). The spermatogenesis and testicular morphology in chronically-infected macaques and humans appeared normal (Mucciaccia et al., 1998; Le Tortorec et al., 2008a). A transitory increase in the plasmatic testosterone level of chronically infected macaques was observed, without any significant modifications of the Luteinizing Hormone (LH) level (Le Tortorec et al., 2008a). In humans, an increase in testosterone level was similarly reported in some chronically-infected patients (Christeff et al., 1992). In patients with AIDS, a decrease in circulating androgens is frequently encountered (Lo & Schambelan, 2001), which can occur in the presence of normal or elevated LH level, indicating a primary testicular failure. To test the hypothesis of a direct effect of the virus on the steriodogenic function of Leydig cells, the susceptibility of this cell type to HIV infection in vitro was examined using a range of HIV and SIV strains with various cell tropisms. The results demonstrated that human Leydig cells are susceptible to some specific HIV-2 and SIV strains but are not infected by HIV-1 strains (Willey et al., 2003; Roulet et al., 2006b). Thus the testosterone level modifications in HIV-1 infected individuals are unlikely to be caused by a direct effect of the virus on Leydig cells but more probably result from the altered hypothalamo-pituitary axis or, in cases where normal pituitary hormones levels are observed, from modified cytokines production within the testis or from direct interactions between Leydig cells and infected macrophages (Le Tortorec et al., 2008a).

During the later stages of the disease, the testis morphology is severely damaged (Dejucq & Jegou, 2001), with different levels of testicular germ cell degeneration leading in some cases to a Sertoli cell only-syndrome. This most probably results from the decrease in testosterone level, elevated body temperature and presence of opportunistic infections rather than from the germ cell infection described in some studies (Da Silva et al., 1990; Nuovo et al., 1994; Mucciaccia et al., 1998), as normal testicular morphology is observed during the asymptomatic stage despite the association of HIV/SIV with testicular germ cells.

To conclude, recent data show that the testis is infected early during the course of HIV infection. This infection is not associated with either any apparent change in testicular morphology or inflammation of the organ (Le Tortorec et al., 2008a). Testicular leucocytes represent the main target cells for the virus, but testicular germ cells also occasionally associate with HIV. This is important to bear in mind for the practice of intra cytoplasmic sperm injection (ICSI) using testicular germ cells from HIV-infected individuals. The presence of HIV receptors on human testicular germ cells and the molecular interactions between these cells and HIV is currently being investigated. Whether the testis constitutes a viral sanctuary despite antiretroviral therapy is under study.

HIV & the accessory glands

Early studies showed evidence of HIV and SIV in immune cells infiltrating the epididymis, prostate and seminal vesicles of men (Da Silva et al., 1990; Pudney & Anderson, 1991; Nuovo et al., 1994) or macaques respectively (Miller et al., 1994) at the AIDS stage. But what happens during the early and asymptomatic stages of the disease has not been studied.

We recently analysed the infection of the epididymis, prostate and seminal vesicles in primary- and chronically-infected macaques. All these MGT organs are infected very early and produce viral particles. The infection persists during the chronic stage and its intensity is positively correlated with the blood viral load. Infected cells are mainly T lymphocytes and to a lesser extent, macrophages. The presence of infected leucocytes during the chronic stage was similarly reported in the epididymis of SIV-infected pigtail macaques (Shehu-Xhilaga et al.,...
The infected immune cells are mainly localized within the stroma of the organs but are also found inserted within the epithelium, a finding most common within the epididymis. Their localization within the secretory epithelium could lead to the release of free viral particles and infected cells in the lumen and therefore in the seminal plasma during ejaculation. In addition, the viral particles produced within the stroma may be sequestered by the epithelial cells – a phenomenon described for prostatic cells in vitro (Dezzutti et al., 2001) – and subsequently released in the seminal fluid. The chronic infection of the accessory glands is associated with T-cell infiltrations and production of inflammatory cytokines. The prostate and seminal vesicles systematically displayed higher levels of infection than the epididymis and the testis. As prostate and seminal vesicles secrete account for respectively 30% and 60% of the seminal fluid (Wolff, 1995), these two organs are likely to represent the main source of virus in semen. In favour of this hypothesis, prostatic massage in men was shown to significantly increase the seminal viral load (Smith et al., 1995). In the same way, the previous studies indicated that vasectomy had little effect on the semen viral load (Anderson et al., 1991; Krieger et al., 1998), suggesting that the testis and epididymis are minor HIV contributors in semen. We recently confirmed that the human prostate is susceptible to HIV-1 infection ex vivo (Le Tortorec et al., 2008b). Interestingly, the prostate was preferentially infected by HIV-1 R5 strains (the sexually-transmitted strains) compared with X4 strains, which are not sexually transmitted and appear during the later stages of the disease (Le Tortorec et al., 2008b).

The male genital tract – a viral reservoir?

HAART aims for durable suppression of viral load, restoration and/or preservation of immunological function and has dramatically enhanced the quality and life span of the individuals who benefit from these treatment. However, the existence of viral sanctuaries prevents the eradication of the virus in the body. A viral sanctuary is either an anatomical (e.g. the brain) or a cellular (e.g. the latently infected resting memory lymphocytes) site, impermeable to the action of one or several antiviral drugs and within which the virus replicates or persists despite treatment. Such sanctuaries are called reservoirs when they replenish the body in free virus or infected cells. Thus when HAART is discontinued, the blood plasma viral load was undetectable under the pressure of the antiretroviral drugs systematically rises again from these reservoirs (Davey et al., 1999).

In semen, some viral inhibitors display sub-optimal concentrations (Kashuba et al., 1999; Taylor & Pereira, 2001; Lafeuillade et al., 2002; Ghosn et al., 2004a; Chan et al., 2008), sometimes leading to the emergence of drug-resistant strains (Eron et al., 1998; Eyre et al., 2000; Taylor et al., 2001, 2003; Ghosn et al., 2004a, 2004b) and to their sexual transmission (Hecht et al., 1998; Grant et al., 2002; Little et al., 2002; Markowitz et al., 2005). The testis is a well-known pharmacological sanctuary into which HIV inhibitors have restricted access (Choo et al., 2000; Livni et al., 2004). The organ is thus a prime candidate for an HIV sanctuary. The fact that the rate, the kinetic of emergence and the diversity of drug-resistant strains diverge between the blood and the seminal plasma (Kroodsma et al., 1994; Eron et al., 1998; Eyre et al., 2000; Ghosn et al., 2004b; La Sala et al., 2007) strongly suggest that HIV in semen arises from a biological compartment separate from blood.

Several studies indicate that the MGT may constitute a viral reservoir responsible for HIV shedding in semen [reviewed in (Dejucq & Jegou, 2001; Dejucq-Rainsford & Jegou, 2004)]. Although in most patients HAART can reduce the semen viral load to an undetectable level (Liuzzi et al., 1999; Barroso et al., 2000; Vernazza et al., 2000; Leruez-Ville et al., 2002b; Bujan et al., 2004; Chan et al., 2008; Ghosn et al., 2008), the persistence of HIV RNA and/or infected cells in semen has been reported in up to 10% of men under various antiretroviral treatment combinations, despite an undetectable blood viral load (Kiesling et al., 1998; Zhang et al., 1998; Dornadula et al., 1999; Mayer et al., 1999; Lafeuillade et al., 2002; Leruez-Ville et al., 2002b; Solas et al., 2003; Vernazza et al., 2007; Marcelin et al., 2008). Most recently, an even higher percentage of men shedding HIV in semen despite effective HAART has been reported: 4 months following the initiation of HAART, 48% of 25 individuals with suppressed blood viral load were releasing HIV in semen and for 16% of them at a high level. Strikingly, this persistent shedding was still observed for 31% of 13 individuals under effective HAART for a median of 10 years (Sheth et al., 2009). The residual viral load detected in semen is generally low but appears to be extremely variable amongst individuals (range of 0.6 log to 5 log of HIV RNA copies/mL) (Dornadula et al., 1999; Mayer et al., 1999; Vernazza et al., 2000; Leruez-Ville et al., 2002b; Bujan et al., 2004; Marcelin et al., 2008; Pasquier et al., 2008).

This persistence of HIV excretion in the semen of a subset of individuals under HAART has potentially important consequences for the transmission of the virus. The critical inoculum for sexual transmission is unknown. A mathematical model indicated a very low risk of heterosexual transmission of three of 10 000 episodes of intercourse for 3 Log of HIV RNA copies per ejaculate (Chakraborty et al., 2001) and HIV heterosexual transmission was estimated to decrease by about 80% follow-
ing HAART (Castilla et al., 2005). Thus the question has been raised as to whether natural conception is an acceptable/negligible risk option for HIV-serodiscordant couples in whom the HIV+ partner is effectively treated (Barreiro et al., 2007) and recently, the Swiss national AIDS Commission stated that serodiscordant couples in whom the infected partner had an undetectable blood viral load under prolonged HAART could safely have unprotected intercourses in the absence of other sexually transmitted infections (STIs) (Vernazza et al., 2008) – a factor known to increase HIV shedding in semen (Dejucq-Rainsford & Jegou, 2004; Zuckerman et al., 2009). This statement has generated a heated debate amongst scientists and patients’ associations. A mathematical model calculated that HIV incidence would quadruple if this advice was followed by 10 000 couples over 10 years (Wilson et al., 2008). It appears from the literature that although drastically reduced, the possibility of transmitting HIV despite an undetectable blood viral load following HAART remains in a subset of patients, as recently illustrated by the case report of an homosexual man under effective HAART who contaminated his partner (Sturmer et al., 2008).

In conclusion, the fact that HIV may persist and shed intermittently in semen from men under effective HAART free of other STIs (Bujan et al., 2004; Marcelin et al., 2008) reinforces the need for testing not only the blood viraemia but also the seminal viral load and this in several distant measurements, to assess the level of risk of a sexual transmission of each individual under HAART. It also stresses the importance of determining the nature of the reservoirs responsible for HIV shedding in semen, to design more effective therapeutic strategies that can eradicate the virus from semen.

**HIV and male reproduction**

In 2008, the majority of the 33 million HIV-infected people worldwide were in their reproductive years. The HIV seropositive male partner in a growing number of serodiscordant couples is seeking assisted reproductive techniques (ART) to have children without contaminating the partner and embryo. ART uses spermatozoa isolated from the infected components in semen (infected immune cells and seminal fluid) and tested negative for viral DNA/RNA (reviewed in (Englert et al., 2004; Bujan et al., 2007a)). Semen quality is an essential criterion for inclusion (as an important number of spermatozoa have to be tested) and this represents a limiting factor for many couples. The semen parameters of HIV+ men have been analysed by several teams. In all studies except one (Garrido et al., 2005), a trend towards semen degradation was observed in men at the advanced stage of the disease with low CD4+ T lymphocytes number in blood (Krieger et al., 1991a, 1991b; Crittenden et al., 1992; Politch et al., 1994; Dondoro et al., 1996; Lasheeb et al., 1997; Muller et al., 1998). As for asymptomatic HIV+ men in the chronic stage, most studies, apart from two (Krieger et al., 1991a, 1991b; Garrido et al., 2005), reported various abnormalities: spermatozoa reduced motility, decreased total number and/or increased morphological abnormal forms (Crittenden et al., 1992; Dondoro et al., 1996; Muller et al., 1998; Dulioust et al., 2002; Nicopoullos et al., 2004; Bujan et al., 2007b; La Sala et al., 2007), lower volume of the ejaculate (Muller et al., 1998; Dulioust et al., 2002; Nicopoullos et al., 2004; Bujan et al., 2007b; La Sala et al., 2007), increased pH of the ejaculate (Bujan et al., 2007b), increased number of round cells in the seminal fluid (Crittenden et al., 1992; Dulioust et al., 2002). The most common findings in recent studies were a decrease in spermatozoa motility and ejaculate volume in healthy HIV+ men (Dulioust et al., 2002; Nicopoullos et al., 2004; Bujan et al., 2007b). An elevated rate of spontaneous abortions was reported in serodiscordant couples of whom the man is HIV+ (Sergerie et al., 2004). Of note is that the majority of these men are taking antiretroviral drugs which may affect semen quality, independently or in addition to the infection. The nucleoside inhibitors of reverse transcriptase (NRTI), in particular thymidine analogues, are suspected to generate modifications of mitochondrial DNA, which could affect spermatozoa motility (Sergerie et al., 2004; La Sala et al., 2007). Recently, a study examined the semen parameters of HIV+ men before and after the initiation of different combination of antiretroviral therapies (van Leeuwen et al., 2008b). A decrease in motile spermatozoa was observed as early as 4 weeks post-treatment initiation, while the semen quality was stable over 1.5 years in untreated HIV+ men (van Leeuwen et al., 2008b), suggesting a direct effect of the antiretroviral drugs on spermatozoa motility. Surprisingly, this effect was observed to be independent of the use of thymidine analogues (van Leeuwen et al., 2008b). – Importantly, the semen volume was unchanged following treatment but was in the lower normal range (van Leeuwen et al., 2008a, 2008b). Further studies will be crucial to the elucidation of the mechanisms responsible for the semen parameter deterioration observed in healthy asymptomatic HIV+ men.

**Conclusions**

Deciphering the origins of HIV in semen is crucial to the development of targeted therapeutic strategies aimed at eradicating the virus in semen. It was recently revealed that MGT organs are infected by HIV during the acute and asymptomatic chronic stages of HIV infection. These
organs most likely contribute an important proportion of the semen viral load.

Future research should be directed to the following areas: (i) determining whether one or several of the infected MGT organs constitute a viral reservoir, which could explain the persistence of HIV in the semen of men under effective treatment with undetectable blood viral load; (ii) determining the aetiology of the semen parameter modifications in HIV+ men under HAART; (iii) deciphering the exact nature of the interactions between HIV, the testicular germ cells and the spermatoozoa, both important issues in the context of ART; (iv) analysing the effect of HIV infection on the seminal plasma composition and its impact on HIV infectivity, which may reveal new mechanisms that could be useful in the fight against the AIDS pandemic as a few studies suggest that seminal plasma factors may influence HIV sexual transmission.

References

Anderson, D. J., Politch, J. A., Martinez, A., Van Voorhis, B. J., Padian, N. S. & O’Brien, T. R. (1991) White blood cells and HIV-1 in semen from vasectomised seropositive men. *Lancet* 338, 573–574.

Baccetti, B., Benedetto, A., Burrini, A. G., Collodel, G., Ceccarini, E. C., Crisa, N. et al. (1994) HIV-particles in spermatozoa of patients with AIDS and their transfer into the oocyte. *The Journal of Cell Biology* 127, 903–914.

Bagasra, O., Freund, M., Weidmann, J. & Harley, G. (1988) Interaction of human immunodeficiency virus with human sperm in vitro. *Journal of Acquired Immune Deficiency Syndromes* 1, 431–435.

Bagasra, O., Farzadegan, H., Seshamma, T., Oakes, J. W., Saah, A. & Pomerantz, R. J. (1994) Detection of HIV-1 proviral DNA in sperm from HIV-infected men. *AIDS* 8, 1669–1674.

Barreiro, P., Castillo, J. A., Labarga, P. & Soriano, V. (2007) Is natural sexual transmission. *International Journal of Andrology* 30, 1141.

Bujan, L., Hollander, L., Coudert, M., Gilling-Smith, C., Vucetich, A., Giubert, J. et al. (2007a) Safety and efficacy of sperm washing in HIV-1-serodiscordant couples where the male is infected: results from the European CREATHe network. *AIDS* 21, 1909–1914.

Byrn, R. A., Zhang, D., Eyre, R., McGowan, K. & Kiessling, A. A. (1997) HIV-1 in semen: an isolated virus reservoir. *Lancet* 350, 1141.

Castilla, J., Del Romero, J., Hernando, V., Marinovich, B., Garcia, S. & Rodriguez, C. (2005) Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. *Journal of Acquired Immune Deficiency Syndromes* 40, 96–101.

Chakraborty, H., Sen, P. K., Helms, R. W., Vernazza, P. L., Fiscus, S. A., Eron, J. I., Patterson, B. K., Coombs, R. W., Krieger, J. N. & Cohen, M. S. (2001) Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. *AIDS* 15, 621–627.

Chan, D. J., Ray, I. E., McNally, L., Batterham, M. & Smith, D. E. (2008) Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs. *Current HIV Research* 6, 477–484.

Cho, J. O., Leake, B., Wandel, C., Imamura, H., Wood, A. J., Wilkinson, G. R. & Kim, R. B. (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. *Drug Metabolism and Disposition* 28, 655–660.

Christoff, N., Gharkakian, S., Thobie, N., Rozenbaum, W. & Nunez, E. A. (1992) Evidence for changes in adrenal and testicular steroids during HIV infection. *Journal of Acquired Immune Deficiency Syndromes* 5, 841–846.

Christy, I. L., Mullen, J. E., Braude, P. R., Rowell, P., Williams, E., Ebling, N., de Ruiter, A., Rice, K. & Kennedy, J. (1998) Assisted conception in HIV discordant couples: evaluation of semen processing techniques in reducing HIV viral load. *Journal of Reproductive Immunology* 41, 301–306.

Clapham, P. R., Reeves, J. D., Simmons, G., Dejucq, N., Hibbitts, S. & McKnight, A. (1999) HIV coreceptors, cell tropism and inhibition by chemokine receptor ligands. *Molecular Membrane Biology* 16, 49–55.

Coombs, R. W., Speck, C. E., Hughes, J. P., Lee, W., Sampoleo, R., Ross, S. O. et al. (1998) Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. *The Journal of Infectious Diseases* 177, 320–330.

Crittenden, J. A., Handelsman, D. J. & Stewart, G. J. (1992) Sperm analysis in human immunodeficiency virus infection. *Fertility and Sterility* 57, 1294–1299.

Curtan, R. & Ball, J. K. (2002) Concordance between semen-derived HIV-1 proviral DNA and viral RNA hypervariable region 3 (V3) envelope sequences in cases where semen populations are distinct from those present in blood. *Journal of Medical Virology* 67, 9–19.

Da Silva, M., Shevchuk, M. M., Cronin, W. J., Armenakas, N. A., Tannenbaum, M., Fracchia, J. A. & Ioachim, H. L. (1990) Detection of HIV related protein in testes and prostates of patients with AIDS. *American Journal of Clinical Pathology* 93, 196–201.
HIV infection of the MGT

A. Le Tortorec and N. Dejucq-Rainsford

and hepatitis C (HCV)-seropositive males: predictors of the success of viral removal after sperm washing. Human Reproduction 20, 1028–1034.

Ghosh, J., Chaux, M. L., Peytavin, G., Rey, E., Bresson, J. L., Goujard, C., Katlama, C., Viard, J. P., Treby, J. M. & Rouzioux, C. (2004a) Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 18, 1958–1961.

Ghosh, J., Viard, J. P., Katlama, C., de Almeida, M., Tubiana, R., Le-tourneur, F. et al. (2004b) Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pretreated HIV-infected men. AIDS 18, 447–457.

Ghosh, J., Chaux, M. L., Peytavin, G., Bresson, J. L., Galimand, J., Girard, P. M., Raffi, F., Cohen-Codar, I., Delfraissy, J. F. & Rouzioux, C. (2008) Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. Journal of Antimicrobial Chemotherapy 61, 1344–1347.

Giordano, R., Magnano, A. R., Zaccagnini, G., Pittoggi, C., Moscufo, N., Lorenzini, R. & Spadafora, C. (2000) Reverse transcriptase activity in mature spermatozoa of mouse. The Journal of Cell Biology 148, 1107–1113.

Grant, R. M., Hecht, F. M., Warmerdam, M., Liu, L., Liegler, T., Petropoulos, C. J., Hellmann, N. S., Chesney, M., Busch, M. P. & Kahn, J. O. (2002) Time trends in primary HIV-1 drug resistance among recently infected persons. The Journal of American Medical Association 288, 181–188.

Gupta, P., Leroux, C., Patterson, B. K., Kingsley, L., Rinaldo, C., Ding, M. et al. (2000) Human immunodeficiency virus type 1 shedding pattern in semen correlates with the compartmentalization of viral quasi species between blood and semen. The Journal of Infectious Diseases 182, 79–87.

Haiwood, N. L. (2004) Predictive value of primate models for AIDS. AIDS Reviews 6, 187–198.

Hanabusa, H., Kui, N., Kato, S., Tagami, H., Kaneko, S., Tanaka, H. & Yoshimura, Y. (2000) An evaluation of semen processing methods for eliminating HIV-1. AIDS 14, 1611–1616.

Hecht, F. M., Grant, R. M., Petropoulos, C. J., Dillon, B., Chesney, M. A., Tian, H. et al. (1998) Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. The New England Journal of Medicine 339, 307–317.

Isobe, T., Minoura, H., Tanaka, K., Shibahara, T., Hayashi, N. & Toyoda, N. (2002) The effect of RANTES on human sperm chemotaxis. Human Reproduction 17, 1441–1446.

Kashuba, A. D., Dyer, J. R., Kramer, L. M., Raasch, R. H., Eron, J. J. & Cohen, M. S. (1999) Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 43, 1817–1826.

Kato, S., Hanabusa, H., Kaneko, S., Takakuwa, K., Suzuki, M., Kuiji, N. et al. (2006) Complete removal of HIV-1 RNA and proviral DNA from semen by the swim-up method: assisted reproduction technique utilizing spermatozoa free from HIV-1. AIDS 20, 967–973.

Kissling, A. A., Fitzgerald, L. M., Zhang, D., Chihay, H., Brettler, D., Eyre, R. C., Steinberg, J., McGowan, K. & Byrn, R. A. (1998) Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir. AIDS Research and Human Retroviruses 14, S33–S41.

Kim, L., Johnson, M., Barton, S., Nelson, M., Sontag, G., Smith, J., Gotch, F. & Gilmour, J. (1999) Evaluation of sperm washing as a...
potential method of reducing HIV transmission in HIV-discordant couples wishing to have children. AIDS 13, 645–651.

Krieger, J. N., Coombs, R. W., Collier, A. C., Koehler, J. K., Ross, S. O., Chaloupka, K., Murphy, V. L. & Corey, L. (1991a) Fertility parameters in men infected with human immunodeficiency virus. The Journal of Infectious Diseases 164, 464–469.

Krieger, J. N., Coombs, R. W., Collier, A. C., Ross, S. O., Chaloupka, K., Cummings, D. K., Murphy, V. L. & Corey, L. (1991b) Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy. The Journal of Infectious Diseases 163, 386–388.

Krieger, J. N., Nirapathpongporn, A., Chaiyaporn, M., Peterson, G., Nikolaeva, I., Akridge, R., Ross, S. O. & Coombs, R. W. (1998) Vasectomy and human immunodeficiency virus type 1 in semen. The Journal of Urology 159, 820–825.

Kroodsma, K. L., Koza, M. J., Hamed, K. A., Winters, M. A. & Merigan, T. C. (1994) Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. The Journal of Infectious Diseases 170, 1292–1295.

La Sala, G. B., Pilotti, E., Nicolì, A., Pinelli, S., Villani, M. T., Ronzi, P., Zendri, E., Re, M. C., Magnani, G. & Casoli, C. (2007) Dynamics of HIV viral load in blood and semen of patients under HAART: impact of therapy in assisted reproduction procedures. AIDS 21, 377–379.

Lafeuillade, A., Solas, C., Hafnoun, P., Chadapaud, S., Hittinger, G. & Lacarelle, B. (2002) Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: Clinical correlations. HIV Clinical Trials 3, 27–35.

Lasheeb, A. S., King, J., Ball, J. K., Curran, R., Barratt, C. L., Afnan, K. R., Kroodsma, K. L., Akridge, R., Ross, S. O. & Finkielsztejn, L. (2002) Decrease in HIV-1 seminal shedding decreases over 96 weeks: a longitudinal study (ANRS EP012). AIDS and Sterility 90, 636–641.

Li, Y., Liu, H., Kim, B. O.,Gattone, V. H., Li, J., Nath, A., Blum, J. & He, J. J. (2004) CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor. Journal of Virology 78, 4120–4133.

Liu, K., Girianni, A., Bagnarelli, P., Clementi, F. & Piazza, M. (1999) A combination of nucleoside analogues and a protease inhibitor reduces HIV-1 RNA levels in semen: implications for sexual transmission of HIV infection. Antiviral Therapy 4, 95–99.

Liviu, E., Berker, M., Hillier, S., Waller, S. C., Ogan, M. D., Discordia, R. P., Rienhart, J. K., Rubin, R. H. & Fischman, A. J. (2004) Preparation and pharmacokinetics of 11C labeled stavudine (d4T). Nuclear Medicine and Biology 31, 613–621.

Lo, J. C. & Schambelan, M. (2001) Reproductive function in human immunodeficiency virus infection. Journal of Clinical Endocrinology and Metabolism 86, 2338–2343.

Marcelin, A. G., Tubiana, R., Lambert-Nicolot, S., Lefèbre, G., Domínguez, S., Bonmarchand, M. et al. (2008) Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. AIDS 22, 1677–1679.

Marina, S., Marina, F., Alcolea, R., Esposito, R., Huguet, J., Nadal, J. & Verges, A. (1998) Human immunodeficiency virus type 1–serodiscordant couples can bear healthy children after undergoing intrauterine insemination. Fertility and Sterility 70, 35–39.

Markowitz, M., Mohri, H., Mehandru, S., Shet, A., Berry, L., Kalyanaraman, R. et al. (2005) Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 365, 1031–1038.

Mayer, K. H., Boswell, S., Goldstein, R., Lo, W., Xu, C., Tucker, L., De Pasquale, M. P., D’Aquila, R. & Anderson, D. J. (1999) Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clinical Infectious Diseases 28, 1252–1259.

Miller, C. J., Vogel, P., Alexander, N. J., Dandekar, S., Hendrickx, A. G. & Marx, P. A. (1994) Pathology and localization of simian immunodeficiency virus in the reproductive tract of chronically infected male rhesus macaques. Laboratory Investigation 70, 255–262.

Mucicacci, B., Filippini, A., Ziparo, E., Colelli, F., Baroni, C. D. & Stefanini, M. (1998) Testicular germ cells of HIV-seropositive asymptomatic men are infected by the virus. Journal of Reproductive Immunology 41, 81–93.

Mucicacci, B., Padula, F., Gandini, L., Lenzi, A. & Stefanini, M. (2005a) HIV-1 chemokine co-receptor CCR5 is expressed on the surface of human spermatozoa. AIDS 19, 1424–1426.

Mucicacci, B., Padula, F., Vicini, E., Gandini, L., Lenzi, A. & Stefanini, M. (2005b) Beta-chemokine receptors 5 and 3 are expressed on the head region of human spermatozoa. The Federation of American Societies for Experimental Biology 19, 2048–2050.

Mucicacci, B., Corallini, S., Vicini, E., Padula, F., Gandini, L., Liuzzi, G., Lenzi, A. & Stefanini, M. (2007) HIV-1 viral DNA is present in ejaculated abnormal spermatozoa of seropositive subjects. Human Reproduction 22, 2868–2878.

Muller, C. H., Coombs, R. W. & Krieger, J. N. (1998) Effects of clinical stage and immunological status on semen analysis results in human immunodeficiency virus type 1-seropositive men. Andrologia 30(Suppl 1), 15–22.

Nicopoulos, J. D., Almeida, P. A., Ramsay, J. W. & Gilling-Smith, C. (2004) The effect of human immunodeficiency virus on sperm parameters and the outcome of intrauterine insemination following sperm washing. Human Reproduction 19, 2289–2297.
HIV infection of the MGT

Nuovo, G. J., Becker, J., Simsr, A., Margiotta, M., Khalife, G. & Shevchuk, M. (1994) HIV-1 nucleic acids localize to the spermatogonia and their progeny: A study by polymerase chain reaction in situ hybridization. American Journal of Pathology 144, 1142–1148.

Paranige, S., Craigio, J., Patterson, B., Ding, M., Barroso, P., Harrison, L., Montelaro, R. & Gupta, P. (2002) Subcompartmentalization of HIV-1 Quasispecies between Seminal Cells and Seminal Plasma Indicates Their Origin in Distinct Genital Tissues. AIDS Research and Human Retrovirus 18, 1271–1280.

Pasquier, C., Daudin, M., Righi, L., Berges, L., Thauvin, L., Berrebi, A., Masiap, P., Puel, J., Bujan, L. & Isopet, J. (2000) Sperm washing and virus nucleic acid detection to reduce HIV and hepatitis C virus transmission in serodiscordant couples wishing to have children. AIDS 14, 2093–2099.

Pasquier, C. I., Moindre, N., Saune, K., Souyris, C., Lavit, M., Daudin, M., Izopet, J. & Bujan, L. (2008) Persistent differences in the antiviral effects of highly active antiretroviral therapy in the blood and male genital tract. AIDS 22, 1894–1896.

Persico, T., Savasi, V., Ferrazzi, E., Oneta, M., Semprini, A. E. & Simoni, G. (2006) Detection of human immunodeficiency virus-1 RNA and DNA by extractive and in situ PCR in unprocessed semen and seminal fractions isolated by semen-washing procedure. Human Reproduction 13, 13.

Pillai, S. K., Good, B., Pond, S. K., Wong, J. K., Strain, M. C., Richman, D. D. & Smith, D. M. (2005) Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. The Journal of Virology 79, 1734–1742.

Ping, L. H., Cohen, M. S., Hoffman, I., Vernoza, P., Seiller-Moisèiwitsch, F., Chaktarborhy, O. et al. (2000) Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. The Journal of Virology 74, 8946–8952.

Piomboni, P. & Baccetti, B. (2000) Spermatozoan as a vehicle for HIV-1 and other viruses: a review. Molecular Reproduction and Development 56, 238–242.

Politch, J. A., Mayer, K. H., Abbott, A. F. & Anderson, D. J. (1994) The effects of disease progression and zidovudine therapy on semen quality in human immunodeficiency virus type 1 seropositive men. Fertility and Sterility 61, 922–928. issn: 0015-0282.

Politch, J. A., Xu, C., Tucker, L. & Anderson, D. J. (2004) Separation of human immunodeficiency virus type 1 from motile sperm by the double tube gradient method versus other methods. Fertility and Sterility 81, 440–447.

Pudney, J. & Anderson, D. (1991) Orchiectomy and human immunodeficiency virus type 1 infected cells in reproductive tissues from men with the acquired immune deficiency syndrome. American Journal of Pathology 139, 149–160.

Pudney, J., Nguyen, H., Xu, C. & Anderson, D. J. (1999) Microscopic evidence against HIV-1 infection of germ cells or attachment to sperm. Journal of Reproductive Immunology 44, 57–77.

Quayle, A. J., Xu, C., Mayer, K. H. & Anderson, D. J. (1997) T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. The Journal of Infectious Diseases 176, 960–968.

Roulet, V., Denis, H., Staub, C., Le Tortorec, A., Delaleu, B., Satie, A. P., Patard, J. J., Jegou, B. & Dejuq-Rainsford, N. (2006a) Human testis in organotypic culture: application for basic or clinical research. Human Reproduction 21, 1564–1575.

Roulet, V., Satie, A. P., Ruffault, A., Le Tortorec, A., Denis, H., Guist’hau, O. et al. (2006b) Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and in vitro. American Journal of Pathology 168, 2094–2103.

Royce, R. A., Sena, A., Cates, W. Jr & Cohen, M. S. (1997) Sexual transmission of hiv. The New England Journal of Medicine, 336, 1072–1078.

Scofield, V., Rao, B., Broder, S., Kennedy, C., Wallace, M., Graham, B. & Poiesz, B. (1994) HIV interaction with sperm. AIDS 8, 1733–1736.

Sergerie, M., Martinet, S., Kiffer, N., Teule, R., Pasquier, C. & Bujan, L. (2004) Impact des inhibiteurs nucéloides de la transcriptase inverse sur l’ADN mitochondrial et génomique des spermatocytes lors de l’Assistance Médicale à la Procréation. Gynécologie Obstétrique et Fertilité 32, 841–849.

Shehu-Xhilaga, M., Kent, S., Batten, J., Ellis, S., Van der Meulen, J., O’Bryan, M., Cameron, P. U., Lewin, S. R. & Hedger, M. P. (2007) The tests and epididymis are productively infected by SIV and SHIV in juvenile macaques during the post-acute stage of infection. Retrovirology 4, 7.

Sheth, P., Kovacs, C., Nemal, K., Jones, B., Laporte, C., Loutfy, M., Burger, H., Weiser, B., Pilon, R. & Kaul, R.; and the Toronto Muco-sal HIV Res Group (2009) Persistent HIV RNA shedding in semen despite effective ART. 16th CROI, Montreal, Canada.

Smith, D. M., Kingery, J. D., Wong, J. K., Ignacio, C. C., Richman, D. D. & Little, S. J. (2004) The prostate as a reservoir for HIV-1. AIDS 18, 1600–1602.

Solas, C., Lafeuillade, A., Halton, P., Chadapaud, S., Hittinger, G. & Lacarelle, B. (2003) Discrepancies between Protease Inhibitor Concentrations and Viral Load in Reservoirs and Sanctuary Sites in Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy 47, 238–243.

Spadafora, C. (1998) Sperm cells and foreign DNA: a controversial relation. BioEssays 20, 955–964.

Sturmer, M., Doerr, H. W., Berger, A. & Gute, P. (2008) Is transmission of HIV-1 in non-viremic serodiscordant couples possible? Journals Antiviral Therapy 13, 729–732.

Tachet, A., Dulioust, E., Salmon, D., De Almeida, M., Rivalland, S., Finkelsztejn, L., Heard, I., Jouannet, P., Sicard, D. & Rouzioux, C. (1999) Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission. AIDS 13, 823–831.

Taylor, S. & Pereira, A. S. (2001) Antiretroviral drug concentrations in semen of HIV-1 infected men. Sexually Transmitted Infections 77, 4–11.

Taylor, S., Back, D. J., Drake, S. M., Workman, J., Reynolds, H., Gibbons, S. E., White, D. J. & Pillay, D. (2001) Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. Journal of Antimicrobial Chemotherapy 48, 351–354.

Taylor, S., Sadiq, S. T., Weller, I., Kaye, S., Workman, J., Cane, P. A., Bennett, J., Copas, A. J., Drake, S. M. & Pillay, D. (2003) Drug-resistant HIV-1 in the semen of men receiving antiretroviral therapy with acute sexually transmitted infections. Journals Antiviral Therapy 8, 479–483.

Vernazza, P. L., Eron, J. J., Cohen, M. S., van der Horst, C. M., Troiani, L. & Fiscus, S. A. (1994) Detection and biologic characterization of infectious HIV-1 in semen of seropositive men. AIDS 8, 1325–1329.

Vernazza, P. L., Troiani, L., Flepp, M. J., Cone, R. W., Schock, J., Roth, P., Boggian, K., Cohen, M. S., Fiscus, S. A. & Eron, J. J. (2000) Potent antiretroviral treatment of HIV-infection results in
suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. *AIDS* 14, 117–121.
Vernazza, P., Daneel, S., Schiffer, V., Decosterd, L., Fierz, W., Klimkait, T., Hoffmann, M. & Hirschel, B. (2007) The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. *AIDS* 21, 1309–1315.
Vernazza, P., Hirschel, B., Bernasconi, E. & Flepp, M. (2008) HIV seropositive persons without sexually transmitted diseases under fully suppressive antiretroviral treatment do not sexually transmit HIV. *Bulletin des médecins Suisses* 89, 165–169.
Willey, S., Roulet, V., Reeves, J. D., Kergadallan, M.-L., Thomas, E., McKnight, A., Jegou, B. & Dejucq-Rainsford, N. (2003) Human Leydig cells are productively infected by some HIV-2 and SIV strains but not by HIV-1. *AIDS* 17, 183–188.
Wilson, D. P., Law, M. G., Grulich, A. E., Cooper, D. A. & Kaldor, J. M. (2008) Relation between HIV viral load and infectiousness: a model-based analysis. *Lancet* 372, 314–320.
Wolff, H. (1995) The biologic significance of white blood cells in semen. *Fertility and Sterility* 63, 1143–1157.
Zhang, H., Dornadula, G., Beumont, M., Livornese, L. J., Van Uitert, B., Henning, K. & Pomerantz, R. J. (1998) Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. *The New England Journal of Medicine* 339, 1803–1809.
Zhang, Q., Shimoya, K., Temma, K., Kimura, T., Tsujie, T., Shioji, M. et al. (2004) Expression of fractalkine in the Fallopian tube and of CX3CR1 in sperm. *Human Reproduction* 19, 409–414.
Zhu, T., Wang, N., Carr, A., Nam, D. S., Moor Jankowski, R., Cooper, D. A. & Ho, D. D. (1996) Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. *The Journal of Virology* 70, 3098–3107.
Zuckerman, R. A., Luchetti, A., Whittington, W. L., Sanchez, J., Combs, R. W., Magaret, A., Wald, A., Corey, L. & Celum, C. (2009) HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. *AIDS* 23, 479–483.